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known as functional abdominal pain syndrome, can be
distinguished from other functional gastrointestinal dis-
orders by its strong central component and relative inde-
pendence from motility disturbances. Centrally mediated
abdominal pain syndrome is a result of central sensitiza-
tion with disinhibition of pain signals rather than
increased peripheral afferent excitability. A newly
described condition, narcotic bowel syndrome/opioid-
induced gastrointestinal hyperalgesia, is characterized by
the paradoxical development of, or increases in, abdominal
pain associated with continuous or increasing dosages of
opioids. Patients only have relief when opioids are with-
drawn. We define both conditions in the context of epide-
miology, pathophysiology, clinical evaluation, and
treatment, emphasizing the importance of a physicianL
patient relationship in all aspects of care.Keywords: Chronic Abdominal Pain; Narcotic Bowel; Functional
Abdominal Pain; Centrally Mediated Pain; Rome IV.
his paper describes our approach and recommen-Tdations related to 2 gastrointestinal (GI) disorders
whose primary symptoms are believed to have a central
determinant—centrally mediated abdominal pain syndrome
(CAPS), formerly known as functional abdominal pain syn-
drome, and a new condition, narcotic bowel syndrome
(NBS)/opioid-induced GI hyperalgesia.Abbreviations used in this paper: CAPS, centrally mediated abdominal
pain syndrome; FD, functional dyspepsia; FGID, functional gastrointestinal
disorder; GI, gastrointestinal; IBS, irritable bowel syndrome; NBS, narcotic
bowel syndrome; SNRI, serotonin-norepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant;
TLR, Toll-like receptor.
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Definition
CAPS is characterized by continuous, nearly continuous,
or frequently recurrent abdominal pain that is often severe
and only rarely related to gut function. CAPS is associated
with loss of function across several life domains, including
work, intimacy, social/leisure, family life, and caregiving for
self or others, and must be present for at least 6 months
before diagnosis.
Like other functional gastrointestinal disorders (FGID),
CAPS cannot be explained by a structural or metabolicdisorder using currently available diagnostic methods.
Abdominal pain can be produced by or attributed to non-
digestive organs, such as those in the urinary or gynecologic
systems, and disorders in these locations that explain such
pain should be excluded before the diagnosis of CAPS can be
established. A substantial proportion of CAPS patients suffer
significant negative contributions from multiple, probably
unnecessary, surgical interventions performed in an attempt
to address their pain complaints,1 and attribute their pain to
“adhesions.” Adhesions can cause symptoms of acute or
subacute obstruction, which in turn cause pain, but there is
no good evidence that adhesions themselves are a cause for
chronic unrelenting pain, such as that seen in CAPS.2
The predominance of pain as the central complaint,
almost to the exclusion of other symptoms, distinguishes
CAPS from other painful FGID, such as irritable bowel syn-
drome (IBS) and functional dyspepsia (FD), primarily by the
poor relationship of pain with food intake or defecation.
CAPS may represent the far end of the spectrum of IBS
severity, where psychosocial factors and more generalized
central hypersensitivity predominate. It is distinguished
from chronic pelvic pain by its abdominal location and from
“abdominal migraine” in that the pain from CAPS is constant
rather than cyclical.
Pain associated with CAPS may be colicky in nature, as in
IBS, although it tends to be more prolonged and widespread.
Another description that is quite common, especially after a
previous surgery, is that pain is burning in character; this
form is particularly challenging to treat.3 CAPS can be
associated with other unpleasant somatic symptoms and
syndromes, such as fibromyalgia and chronic fatigue syn-
drome. While not part of the diagnostic criteria, psycho-
logical comorbidities are common when pain is persistent
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chronic pain behaviors, and dominate the patient’s life. 3
Epidemiology
CAPS is considered less common than other FGIDs, such
as functional heartburn, FD, or IBS, with prevalence data
ranging from 0.5% to 2.1%.4 CAPS seems to be between 1.5
and 2 times more common in women,4,5 and its prevalence
reaches a peak in the fourth decade of life (3544 years in
the US householder survey) and then decreases with age.6
Approximately 80% of CAPS patients have consulted a
physician, and half had seen a physician between 1 and 3
times per year specifically for abdominal pain,4,7 4 times
more frequently than people without abdominal complaints.
CAPS patients in the United Kingdom required 5.7 consul-
tant visits, completed 6.4 endoscopic or imaging in-
vestigations, and underwent 2.7 surgical interventions
(primarily hysterectomy and exploratory laparotomy) dur-
ing a follow-up period of 7 years.8 In the United States, CAPS
patients missed work a mean of 11.8 days in the previous
year, 3 times more than subjects without abdominal
symptoms, and “felt too sick to go to work” at the moment of
the survey in 11.2% of cases, about 3 times more frequently
than respondents without FGIDs.4
D1. Diagnostic Criteriaa for Centrally Mediated Abdom-
inal Pain Syndromeb
Must include all of the following: Continuous or nearly continuous abdominal pain
 No or only occasional relationship of pain with
physiological events (eg, eating, defecation, or
menses)c
 Pain limits some aspect of daily functioningd
 The pain is not feigned
 Pain is not explained by another structural or
functional gastrointestinal disorder or other medical
condition
aCriteria fulfilled for the last 3 months with symptom
onset at least 6 months before diagnosis.
bCAPS is typically associated with psychiatric comor-
bidity, but there is no specific profile that can be used for
diagnosis.
cSome degree of gastrointestinal dysfunction may be
present.
dDaily function could include impairments in work, in-
timacy, social/leisure, family life, and caregiving for self
or others.
Pathophysiology
The biology of CAPS is likely similar to other chronic
visceral pain disorders, such as IBS, FD, and interstitialcystitis. While these disorders are all defined by discrete
symptom criteria, they have in common comorbidity with
other pain syndromes, predisposing life events, and treat-
ment responses. As with many chronic somatic pain disor-
ders, CAPS does not fit easily into the traditional categories
of neuropathic or inflammatory pain. Rather, alterations in
modulatory and motivational pain dimensions play a major
role in both the generation and perpetuation of CAPS.
Altered central sensory processing in gastroin-
testinal pain syndromes: lessons learned from irri-
table bowel syndrome and functional dyspepsia. The
brain receives interoceptive input from the abdominal
viscera, which is then combined with cognitive, emotional,
and other sensory information for conscious interpretation
in the anterior insula. Neuroimaging studies in IBS are
consistent with an abnormality in central processing of pain
signals, with functional and structural abnormalities noted
in sensory (mid-cingulate, insular, and somatosensory
cortices, and thalamus), emotional arousal (anterior cingu-
late cortex, amygdala), and prefrontal cortical modulatory
regions. Modulation of descending pain regulatory pathways
in the brainstem by these cortical regions can lead to
exaggerated sensitivity to both noxious and innocuous
stimuli. Evidence that patterns of brain activation during
anticipation of experimental pain are abnormal in IBS
further supports this pathophysiologic model. Patients with
FD show similar abnormalities compared with healthy
control subjects.9
One way in which CAPS differs from IBS and FD is that
the pain symptoms are, by definition, reported as more
constant and unrelated to peripheral events, such as food
intake or defecation. This suggests that, unlike IBS and FD,
the phasic, physiologic visceral afferent input from the gut
plays a lesser role in symptom generation. These observa-
tions, along with the common responsiveness of CAPS
symptoms to low-dose tricyclic antidepressants (TCA), rai-
ses the question of whether some CAPS patients have a
peripheral or gut-based neuropathic pathophysiologic pro-
cess. Unfortunately, neither the characteristically enlarged
pain referral areas nor the response to TCAs (which work
on both peripheral and central neuropathic pain conditions)
make it possible to differentiate between these possibilities.
However, even in the setting of a peripheral insult, once
central sensitization is established, symptoms can persist in
the absence of ongoing abnormal peripheral stimulation or
worsen with minimal stimulation.10 Because no consistent
initiating triggers are noted in CAPS, and the risk factors
seem to be primarily psychosocial, it is presumed that
central processes, such as altered descending pain modu-
lation, are responsible for the chronicity of CAPS.11
Altered brain structure in chronic pain. Altered
brain structure has also been described in multiple visceral
and somatic pain disorders. In women with IBS, increased
cortical thickness in the somatosensory cortex and
decreased cortical thickness in regions of pain processing,
including the insula and anterior cingulate cortex, is
observed.12 IBS symptom severity was negatively correlated
with the cingulate thickness, suggesting a role for loss of
neural density in symptom generation. Using another metric
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decreased volumes in widespread regions, including the
insula, amygdala, cingulate, and brainstem, with early life
trauma playing a role in these differences.13 Patients with
FD also exhibit altered brain structure, with decreased gray
matter density in multiple brain regions, including the
insula and prefrontal cortex.14 Both IBS and FD have been
shown to have abnormal structure of the brain’s white
matter tracts, with similar areas involved in the processing
of pain and emotion. The role of structural change in func-
tional pain disorders is not clear, with some debate as to
whether these changes are pre-existing vulnerability factors
for chronic pain, or side effects of the pain itself. Given the
severity and chronicity of pain symptoms in patients with
CAPS, the likelihood that structural brain changes exist is
high.
Genetic and environmental vulnerability to cen-
trally mediated abdominal pain syndrome. Animal
models and human studies suggest that complex genetic
influences play an important role in the predisposition to
chronic pain. It is considered likely that this predisposition
is a combination of genetic, environmental, and behavioral
factors. Early evidence suggests genes related to serotonin
reuptake, mucosal barrier function, pro- and anti-
inflammatory cytokines, among others, may be involved.
Clinical and preclinical evidence suggests that there is a
strong association of aversive early life events and certain
types of psychosocial stressors with increased pain reports
and changes in brain function among patients with
FGID.15,16 The combination of genetic factors, learned
behavioral factors, adverse early life events, and adult stress
might determine, in part, the effectiveness of endogenous
pain modulation systems and thereby influence develop-
ment of CAPS.
Psychological factors can amplify the experience of
pain, lending further rationale for the use of psychological
interventions for the management of CAPS. For example,
depression and anxiety mediate the effect of pain on
function in chronic low back pain17 and a trauma history
can negatively influence pain experience, coping, and the
doctorpatient relationship.18 Finally, there is strong
empirical support for the importance of pain catastroph-
izing,19 fear avoidance behavior,20 self-efficacy,21 lack of
perceived control,22 and passive pain coping23 on pain
experience.
Clinical Evaluation
A wide range of disorders produce abdominal pain, and
the clinician should be aware of the large number of dif-
ferential diagnoses.24 Of great importance is the duration
of symptoms—the diagnostic approach to patients with
acute abdominal pain is completely different from patients
with long-standing abdominal pain. Evaluation should
consist of a clinical and psychosocial assessment, obser-
vation of symptom-reporting behaviors, a physical exami-
nation, and, in the absence of alarm features, conservative
efforts to exclude other medical conditions in a cost-
effective manner. Notably, for patients meeting diagnostic
criteria for CAPS who exhibit a longstanding history of painbehaviors, certain psychosocial correlates and no alarm
features, the clinical evaluation usually fails to disclose any
other specific medical etiology to explain the illness and, in
line with this, clinical investigations could be limited.25
However, occasionally the evaluation might incidentally
identify other medical conditions of uncertain relation to
the presentation (eg, hepatic and/or renal cysts or gall-
stones). Efforts then must be directed toward under-
standing the relative contributions of CAPS, and the elicited
findings or diagnoses, to the pain reported. A number of
clinical and behavioral features typify, but are not specific
for, CAPS. Their presence may aid in the planning of
diagnostic testing and are essential to designing the
treatment approach.
Medical History
Description of the pain. A carefully taken history
focused on the description of pain is crucial in these
patients, as pain is the central feature. Typically, the pain in
CAPS is constant, nearly constant, or frequently recurring,
with pain occurring more or less every day. The pain is
associated with loss of daily functioning, which is often quite
severe (eg, work and school absenteeism, limitations in
social activities). The pain is not, or only occasionally,
associated with physiological events, such as bowel move-
ments, eating, or menses. In addition, the patient often
describes the pain in emotional terms; the pain involves a
large anatomic area, rather than a precise location. Patients
with CAPS also frequently complain of several other painful
extraintestinal symptoms (eg, musculoskeletal pain) and
often there is a continuum of painful experiences beginning
in childhood or recurring over time.25
Symptom behaviors. Although there are symptom-
related behaviors that typify CAPS, they are neither sensi-
tive nor specific and have limited diagnostic value, as they
might also occur in patients with a structural disease. These
behaviors are usually considered maladaptive but poten-
tially modifiable (Figure 1).
Presence of other medical diagnoses. Symptoms
compatible with CAPS may coexist with other structural or
functional diagnoses, or at least these diagnoses have been
obvious or even dominating the picture initially. This
coexistence reflects a transition from more peripherally
based afferent neural activity due to bowel dysfunction, to a
pattern of central disinhibition usually associated with more
constant pain. A proportion of patients with CAPS may also
affirm abnormal bowel habit, but without any association
with their constant and severe pain. Patients with a struc-
tural painful disease might, over time, develop a condition
more compatible with CAPS, when the pain pattern evolves
as more continuous, severe, and nonresponsive to existing
treatment alternatives.
Concurrent psychosocial features and clinical/
psychocial assessment. Patients with CAPS show no
consistent psychological profile, but psychosocial diffi-
culties/problems often contribute to poor health outcomes
in this group of patients. Many patients with CAPS fulfill
diagnostic criteria for comorbid psychiatric diagnoses,
including anxiety, depression, and somatization,26 but,
Figure 1. Symptom-
related behaviors are
common in CAPS. These
symptoms lack sensitivity
and specificity to a CAPS
diagnosis, but awareness
of these behaviors can
facilitate the clinical
examination.
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with CAPS are often reluctant to accept that these could
contribute to their symptom profile. A history of unre-
solved losses (eg, death of a parent, surgery),27 as well as
a history of sexual and physical abuse, are common fea-
tures in patients with CAPS,28 but it should be noted that
their presence is by no means diagnostic of CAPS, but
rather can explain the severity of the condition. Inde-
pendent of diagnosis, a history of abuse predicts poor
health outcomes.29 By answering a few questions, the
physician can appraise effectively the clinical features of
CAPS, identify the key psychosocial contributions to the
disorder, and increase confidence in the diagnosis30
(Figure 2).Physical Examination
The physical examination does not establish a diagnosis
of CAPS, and only rarely does it identify other etiologies inchronic pain patients. Nevertheless, there is no substitute
for examining the patient to clarify pain location and radi-
ation patterns, and to legitimize the patent’s symptoms.
Additionally, in the previously uninvestigated patient,
important physical findings can direct the diagnostic
workup and might expeditiously lead to an underlying cause
(eg, abdominal wall pain).24,31
Investigations. Tests to exclude other diagnoses
should not be done on a routine basis, but based only on the
presence of “alarm signs” or “red flags” indicating a clinical
suspicion of organic disease.32 A minimal diagnostic workup
should include routine laboratory tests to exclude inflam-
mation and signs of GI bleeding (anemia, fecal blood loss). If
alarm features are identified by history, physical examina-
tion or laboratory screening investigations, the physician
should examine the patient for causes of abdominal pain
other than CAPS. However, in the absence of alarm features
or screening abnormalities, no further tests are indicated,
and in the presence of longstanding stable symptoms, theFigure 2. These questions
can provide a clinical and
psychosocial overview of
the patient’s condition to
support the diagnosis of
CAPS and to assist in
formulating a treatment
plan.
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diagnosis have been met.33 The appropriateness of this
approach is supported by several recent studies demon-
strating that diagnostic failures are very rare,34 and that the
health-related quality of life for patients with an FGID does
not increase after the patients have undergone in-
vestigations.35 Figure 3 displays an algorithm for the eval-
uation of CAPS.Treatment
The management of CAPS relies on establishing an
effective patientphysician relationship,36 following a gen-
eral treatment plan (eg, setting treatment goals and basing
treatment on symptom severity), and offering management
that encompasses a combination of treatment options,
including pharmacologic and/or psychologic treatments37
(Figure 4).Establishing an Effective PatientPhysician
Relationship
Patients and physicians must share responsibility for
the treatment. For example, patients must hold realistic
expectations about treatment and the provider can help
adjust expectations through questions such as “How do you
believe I can be helpful to you?” Patients must be ready to
enter into a therapeutic relationship with a provider—in
CAPS, the focus needs to move away from evaluation and
cure toward facilitating adaptation to constant symptoms.
Finally, patients must be ready to take responsibility in
their care—this is associated with improvement in clinical
outcomes.
Physicians and patients both benefit when physicians
listen actively, accept CAPS as a true disorder, offer
empathy, use an open-ended question style with matching
body language, validate the patients’ feelings,38 set realistic
treatment goals, educate the patient about the nature of
their condition, reassure, negotiate and provide choicesaround treatment rather than directives, maintain bound-
aries, and are aware of time constraints.
Some additional principles to consider:
1. Base treatment on symptom severity and degree of
disability. If pain is continuous and severe, or if the
patient is reluctant to participate in a psychological
intervention, antidepressants (eg, TCAs or serotonin-
norepinephrine reuptake inhibitors [SNRIs]) are
used for their analgesic effects.
2. Know when to refer to a mental health professional.
Present the psychological referral as a means to help
the patient manage the pain and reduce the emotional
distress encumbered by the symptoms. Medical care
should continue concurrent with psychological
treatment.
3. Referral to a multidisciplinary functional GI or pain
treatment center. Multidisciplinary functional GI or
pain treatment centers provide comprehensive
assessment and treatment. Care must be taken to
avoid pain centers that focus on opioid treatment,
which is contraindicated and raises the risk for NBS.General Principles of Treatment
Pharmacologic therapy. Pharmacologic therapy for
CAPS can be employed along with the general treatment
approaches outlined here. Medical treatment is most effec-
tive within the context of a well-developed patient
physician relationship,36 and a comprehensive bio-
psychosocial39 treatment plan (Table 1).
Tricyclic antidepressants. TCAs are the most widely
used psychotropic agents for treating medical (eg, post-
herpetic neuralgia, diabetic neuropathy) and functional
pain syndromes (eg, fibromyalgia).40–44 Their analgesic ef-
fect is probably unrelated to the antidepressant effect
because these drugs are helpful in many pain syndromes
where psychopathology is less prominent or absent, andFigure 3. The differential
diagnosis for chronic
abdominal pain is broad.
The evaluation of sus-
pected CAPS can be
simplified using this algo-
rithm. (Reprinted from
Sperber AD, Drossman
DA. Functional abdominal
pain syndrome: constant
or frequently recurring
abdominal pain. Am J Gas-
troenterol 2010;105:770-
774).
Figure 4. Themanagement
of CAPS relies on a strong
patient-physician relation-
ship, early incorporation of
nonpharmacological thera-
pies, and referral to behav-
ioral health specialists
when needed.
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dosages). Improvement in pain as with desipramine in IBS
was not related to blood levels or medication dosage.45
TCAs (eg, amitriptyline, imipramine, desipramine, dox-
epine, and trimipramine) are helpful in relieving pain and
reducing IBS symptoms in moderate to severe cases,40,46
with a pooled relative risk for clinical improvement with
TCA therapy of 1.93. The most common side effects of TCAs
include sedation or sometimes agitation, hypotension, con-
stipation, urinary retention, xerostomia, and effects on sleep
such as insomnia or nightmares.
Selective serotonin reuptake inhibitors. Selective
serotonin reuptake inhibitors (SSRIs) have lesser analgesic
effect compared with TCAs, likely due to a lack of effect on
noradrenalin synaptic levels, as evidenced by experimental
models.47 One multicenter study compared amitriptyline (a
TCA) to citalopram (an SSRI) and placebo among patientswith
FD48 and showedsignificant reduction in symptoms relative to
placebowith the TCA, but not the SSRI. SSRIs are probably less
potent visceral analgesics than TCAs or SNRIs, but they will
have significant effects on global well-being and anxiety-
specific GI symptoms. Side effects may include nausea and
diarrhea; sexual dysfunction with decreased libido andTable 1.Antidepressant treatment for CAPS
Tricyclic antidepressants
Treatment targets Pain, depression P
Adverse events Sedation, hypo-tension, constipation,
dry mouth/eyes, arrhythmias,
weight gain, sex dysfunction
In
Risk from overdose Moderate L
Dose adjustment Yes Ndelayed orgasm; and neurologic/psychiatric symptoms, such
as anxiety, nervousness, tremor, insomnia, and nightmares.
Serotonin-norepinephrine reuptake inhib-
itors. The available SNRIs (eg, duloxetine, venlafaxine,
desvenlafaxine, and milnacipran), while used for depression,
are being used increasingly for treating chronic pain. Their
dual effects (analgesic and antidepressant) make them an
attractive choice in depressed patients with pain syn-
dromes,49 but their benefit for CAPS is theoretical (Table 1).
Decisions relating to which antidepressant to use (or
whether to combine them) will depend on several fac-
tors, including the agent’s potential to address pain and
side effects of diarrhea or constipation. These factors
depend largely on the main receptor sites of action
(Table 2).
Atypical antipsychotics. Quetiapine has been used in
lower doses for treating medical patients with anxiety,
sleep disturbance, and associated psychological comorbid
symptoms, and for augmentation treatment with painful
disorders like fibromyalgia.50 It can benefit patients with
chronic abdominal pain by reducing anxiety, restoring
normal sleep patterns, and possibly through a direct
analgesic effect.51,52 Overall, it appears to augment theSelective serotonin
reuptake inhibitors
Serotonin-norepinephrine
reuptake inhibitors
ain, depression, panic, anxiety,
obsessive compulsive disorder
Pain, depression
somnia, agitation, diarrhea,
night sweats, headache,
weight loss, sex dysfunction
Nausea, agitation, dizzi-ness,
sleep disturbance, fatigue,
liver dysfunction
ow Minimal
ot usual Not usual
Table 2.Antidepressant Receptor Site Effects
Norepinephrine 5-hydroxytryptamine Histamine Acetylcholine
TCAs (25-150 mg)
Amitryptaline (3) þþþ þþþ þþþþ þþþþ
Doxepin (3) þþ þþþ þþþþ þþ
Desipramine (2) þþþ þþþ þ þ
Nortriptyline (2) þþþ þ þþ þþ
SSRIs (1-2 pills)
Citalopram nil þþþþ nil nil
Escitalopram nil þþþþ nil nil
Fluoxetine nil þþþþ nil nil
Paroxetine nil þþþþ nil nil
Sertraline nil þþþþ nil nil
SNRIs (variable)
Venlafaxine þþ þþ nil nil
Duloxetine þþþ þþþ nil nil
Milnacipran þþþ þþ nil nil
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adequate clinical response.
Miscellaneous psychotropic medications. Mir-
tazapine, a tetracyclic antidepressant has increased norad-
renergic activity and 5-HT1A serotonergic activity, which
makes it helpful as an antiemetic and appetite stimulant,
leading to weight gain, as in patients with FD.53 Buspirone is
a nonbenzodiazepine, anti-anxiety agent that can augment
the effect of antidepressants, and with 5HT1 agonist ef-
fects,54 it can improve symptoms of FD.55
Anticonvulsants. Anticonvulsants, such as carbamaz-
epine, lamotrigine, and, more recently, the a2D ligand
agents, gabapentin and pregabalin, have been evaluated in
some chronic pain syndromes, but have not been studied for
chronic abdominal pain or CAPS.56,57 Brain imaging studies
showed that pregabalin reduced chronic pain reports and
this was associated with a reduction of the usually increased
functional connectivity seen between brain regions in
chronic pain states.58
Analgesics. Most analgesics (eg, aspirin and nonste-
roidal anti-inflammatory drugs) offer little benefit because
their actions are somatic in location. Narcotic analgesics
should be avoided because of the likelihood of addiction and
the possibility of narcotic bowel syndrome and other GI side
effects.59
Augmentation treatment. With CAPS, sequencing
high dosages of one medication after another may fail due to
incomplete response or side effects. Augmentation involves
the use, usually at lower dosages, of 2 or more treatments
that act on different receptor sites or areas of the brain to
enhance the therapeutic effect.54 Augmentation treatment
using multiple psychotropic agents should be prescribed in
consultation with or by a psychiatrist, psychopharmacolo-
gist, or medical physician with advanced training in the use
of these medications.
Psychological treatment and antidepressants. An
effective augmentation approach is to combine antide-
pressants with psychological treatment. Antidepressants
can improve pain and vegetative signs of depression,
while psychological treatments improve higher levels ofbrain functioning, such as coping, reappraising of mal-
adaptive cognitions, and cognitive adaptation to previous
losses and trauma. Psychological treatment can improve
adherence to taking a medication, and conversely taking
an antidepressant can increase psychic energy to improve
the efficiency of the work of therapy. Studies have shown
that antidepressants work in subcortical areas, such as
the anterior cingulate cortex and insula, to improve con-
nectivity to prefrontal and other cortical areas (“bottom
up” effects), and psychological treatments work on pre-
frontal or cognitive (“executive”) areas, “top-down” ef-
fects.60 The effect size difference for combined treatment
can be 50% or more than either monotherapy
treatment.61,62 Four classes of psychotherapy hold
the most promise in CAPS: cognitivebehavioral therapy,
psychodynamicinterpersonal therapy, mindfulness/
acceptance-based therapies and hypnotherapy. These are
typically administered individually by a health psycholo-
gist or other mental health provider familiar with GI
physiology, always in conjunction with medical treatment.Other Interventions
Patients seldom gain substantial relief from their
symptoms and seek out alternative treatment approaches.
However, peripherally based treatments are unlikely to be
more effective than centrally targeted modalities.
There is no evidence to support spinal manipulation, and
minimal evidence to support transcutaneous electrical
nerve stimulation or acupuncture, although the latter may
have some putative effect on the opioid system and could be
recommended. Neurolytic celiac plexus blockade in benign
disease has been restricted to chronic abdominal pain from
suspected structural sources, such as chronic pancreatitis,
and with only modest success. Many patients with CAPS
exhibit erythema ab igne, indicating the excessive use of hot
water bottles, electric heating pads, etc, suggesting that heat
seems to provide some degree of pain relief despite any
direct evidence. Although uncontrolled studies suggest a
significant diagnostic and therapeutic benefit of
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inal pain,63 the outcome may be placebo-related, and the
detection of unsuspected diagnoses is rare.64 Repeated
adhesiolysis should be minimized to those situations where
it is likely that the adhesions are having a clinical effect such
as intermittent small bowel obstruction.
D2. Narcotic Bowel Syndrome/Opiate-
Induced Gastrointestinal Hyperalgesia
Definition
NBS is characterized by the paradoxical development of,
or increases in, abdominal pain associated with continuous
or increasing dosages of opioids.59 NBS can occur in patients
with functional GI disorders or chronic GI diseases (eg, IBD,
chronic pancreatitis), with painful malignant or nonmalig-
nant diseases, or even in patients receiving high dosages of
narcotics when recovering from surgery.65 Patients with
NBS will have relief or meaningful improvement of their
pain when the opioids are withdrawn.65
Epidemiology
Opioids are the most commonly prescribed drug cate-
gory in the United States.66 Most pain clinicians will not see
NBS; its recognition is more familiar in GI practices where
patients on opioids are referred for severe abdominal pain
and presumed to have an FGID.67
D2. Diagnostic Criteriaa for Narcotic Bowel Syndrome/
Opioid-Induced Gastrointestinal Hyperalgesia
Must include all of the following:1. Chronic or frequently recurring abdominal painb
that is treated with acute high-dose or chronic
narcotics
2. The nature and intensity of the pain is not
explained by a current or previous GI diagnosisc
3. Two or more of the following:
a. The pain worsens or incompletely resolves
with continued or escalating dosages of
narcotics
b. There is marked worsening of pain when the
narcotic dose wanes and improvement when
narcotics are re-instituted (soar and crash)
c. There is a progression of the frequency, dura-
tion, and intensity of pain episodes
aCriteria fulfilled for the last 3 months with symptom
onset at least 6 months before diagnosis.
bPain must occur most days.
cA patient may have a structural diagnosis (eg, inflam-
matory bowel disease, chronic pancreatitis), but the
character or activity of the disease process is not suffi-
cient to explain the pain.Pathophysiology
Physiological features. While there are several puta-
tive mechanisms to explain the central hyperalgesia of
opioids, perhaps the most favored is that of glial cell acti-
vation in the dorsal horn of the spinal cord, which
up-regulates peripheral nociceptive signals going ceph-
alad.68 Dorsal horn glia (astrocytes and microglia), when
activated, produce proinflammatory cytokines, nitrous ox-
ide, and excitatory amino acids. This leads to central
hyperalgesia with enhanced pain. Glial cell activation occurs
in response to inflammation or infection, drugs such as
morphine, an endogenous chemokines (fractalkine), from
peripheral injury, other activated glial cells, or even in
response to signals from the central nervous system, which
opens the possibility for central effects of stress on
peripheral pain facilitation.69 The glia cell, the immuno-
competent cell of the central nervous system, are activated
via Toll-like receptors (TLR4), which modify the pharma-
codynamics of opioids by eliciting a proinflammatory reac-
tion with disruption of glutamate homeostasis.70 Certain
pharmacologic agents could potentially interrupt this pain-
inducing pathway via disruption of TLR4 and TLR2
signaling,70 including TCAs.71
Another potential contributing factor is the bimodal
excitatory and inhibitory opioid modulation system in the
dorsal horn. The Gi/o protein inhibitory receptor is acti-
vated, leading to analgesia with short-term opioid use, but
also Gs protein excitatory receptor can be activated to
produce hyperalgesia in some individuals when chronic
high dosages of opioids are used.72 The Gs-coupled
excitatory opioid receptors become progressively sensi-
tized during chronic exposure of dorsal root ganglia to
opioid agonists over time leading to tolerance of inhibi-
tory pain effects and ultimately hyperalgesia via Gs-
coupled activation. Clinically, the use of prolonged high-
dose narcotic agonists may produce opioid hyperalgesia
and NBS.
Descending pathways originating from the cingulate and
prefrontal cortex, the rostral ventral medulla and peri-
aqueductal gray can produce antinociception, although
descending tracts through the dorsolateral funiculus can
enhance pro-nociceptive input.73 These responses have
been demonstrated to occur via activation or inactivation of
“on” and “off” cells in the rostral ventral medulla. Activation
of the off cells produces an inhibition of nociceptive input,
while activation of the on cells is believed to facilitate
nociceptive processing within the rostral ventral medulla
and descending projections to the spinal cord.74 An animal
model for NBS has been described in which morphine has
led to the development of central and visceral hyper-
algesia.75 Minocycline, a known inhibitor of microglia acti-
vation, resulted in normalization of the hyperalgesia during
the morphine treatment.Clinical Evaluation
Patients with NBS most often report moderate to severe
colicky or constant abdominal pain, which is poorly local-
ized. They may have been prescribed opioids initially for
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bowel disease, CAPS) or extra-abdominal (eg, orthopedic
pain, fibromyalgia, migraine headaches) conditions, or even
develop increasing pain after surgery. Although initially
receiving opioids for intermittent pain, patients soon
develop tolerance and tachyphylaxis, which require esca-
lating doses for continued clinical benefit. Eventually,
reduced or no pain periods diminish and the abdominal pain
becomes constant and severe despite ongoing treatment.59
The pain may be associated with other GI symptoms
consistent with opioid bowel dysfunction, including nausea,
vomiting, heartburn, constipation, and either overflow
diarrhea or diarrhea from opioid withdrawal. Associated
diagnoses may include gastroparesis, pseudo-obstruction,
and opioid-induced constipation.
Patients may show psychosocial disturbances, including
anxiety, depression, somatization, post-traumatic stress
disorder, and personality disorders often associated with
high health care use and increased health care expenditures
due to procedures, surgery, and medications.65 Although
these features are not a part of the diagnostic criteria of NBS
per se, awareness of them is helpful in treatment planning.
Patients may have had extensive laboratory studies
done, which are usually normal, and radiologic studies
might show colonic fecal retention. Cross-sectional imaging
has usually been done to exclude obstruction, pancreatitis,
inflammatory or ischemic bowel, or other intra-abdominal
pathology. These negative studies, in addition to a focused
history and physical examination and meeting the diag-
nostic criteria, should be adequate to make a diagnosis of
NBS.
NBS is a positive diagnosis that can occur solely (eg, in a
patient developing abdominal pain after an operation or
treatment for back pain), or it can be present alongside
other structural GI diseases, when the pain is out of pro-
portion to the pain inferred to be from the structural dis-
ease. For example, patients may have had pancreatitis with
resolution of the lipase but worsening pain from the NBS, or
may have inflammatory bowel disease without complica-
tions of bowel obstruction, deep ulcers, or serologic evi-
dence for inflammation. The diagnosis is particularly
challenging when the patient has active bowel disease and is
also on opioids in the clinical setting of worsening abdom-
inal pain. As such, there is no specific diagnostic evaluation
recommended other than the good clinical judgment
required to evaluate the activity of other comorbid medical
diseases. In these cases, it might be reasonable to detoxify
patients as a therapeutic trial to see if NBS is present.
There is no particular time frame or dosage of opioids
required for diagnosis because NBS can occur within a few
weeks and with varying dosages. Therefore, the diagnosis is
based on the development of the clinical features in a setting
of opioid use, and it is observed that patients most often are
taking, on average, 75 mg or more daily of oral morphine
equivalent.65
A subset of patients with abdominal pain on opioids may
have opioid use disorder.76 These patients take opioids in
larger amounts than intended, with a persistent desire to
continue and crave for them, and fail to fulfill normal work,school, or home obligations.77 Patients with these features
should be referred to a substance abuse program, as the
likelihood of successful management of these patients in a
medical setting is extremely low.
Treatment
Understanding the patient. It helps to understand
that most patients with NBS want to be treated, but might
not see reduction of opioids as a logical option. These pa-
tients believe that opioids have been “all that has helped”
and fear being abandoned with worsening pain. They also
feel stigmatized by others who they perceive see them as
“drug seeking” or having a psychiatric problem.
Clinician considerations in the treatment. A sound
patientphysician relationship through good communica-
tion skills is a prerequisite to the treatment of patients with
NBS.78 The clinician must feel committed to work with these
patients and be aware of possible negative feelings toward
patients that s/he perceives as “difficult.”
Educating about the treatment. Once a commitment
is made to treat, the physician must engage with the patient
and discuss NBS and options for treatment, including opiate
detoxification. The Current Opioid Misuse Measure79 is a
useful tool to determine the severity of misuse and likeli-
hood of detoxification. The treatment protocol discussed
here involves complete detoxification because there is only
evidence of clinical improvement with this approach65 and
no evidence that NBS can be treated with continuation of
opioids.
Negotiating the treatment requires mutual trust and
patient engagement toward a shared plan of care,59 which
can be facilitated through empathy, acceptance, and vali-
dation of the reality of the pain and its impact on the pa-
tient’s life, an open dialogue about the mechanism of NBS
and the rationale for the recommended treatment, including
the specifics of opioid detoxification and eliciting/address-
ing the patient’s concerns directly. If the patient says opioids
have been the only effective treatment, the clinician can note
that, despite using high-dose opioids, the patient is still not
achieving benefit or it is incomplete; describe the value of
more effective treatments for the pain (eg, tricyclic or SNRI
antidepressants and central anxiety-reducing agents) to use
during and after detoxification; note that once beginning the
program, the protocol for opiate reduction will not change,
but alternative agents can be used for pain and anxiety;
provide realistic goals from the detoxification, which are to
improve the pain (not necessarily achieve complete pain
resolution) over the course of months; enlist friends and
family members in discussions of the goals and treatment to
ensure their support during the process and also to help
prevent relapse; indicate the role of ancillary providers (eg,
psychologists or psychiatrist, primary care physician, and
physician assistant) to help in the process; and reaffirm
their willingness to continue with the patient in the care
regardless of the outcome.
Treatment plan is provided in Table 2.
Clinical outcome. The single outcome study in NBS
detoxification included 39 patients who were systematically
detoxified in an inpatient facility during a 7-day period with
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“responders”; 11% percent had worse pain after detoxifi-
cation.65 This committee believes that inpatient programs
provide much more control over detoxification, and can
usually be done in 1 week rather than outpatient programs,
which take several weeks.
Conclusions
We described a set of GI pain disorders with a central
determinant. These disorders are increasingly common and
complex and must be approached from a comprehensive
biopsychosocial model. The doctorpatient relationship is
at the core of all evaluation and management decisions.
CAPS is distinguished by chronic, unrelenting pain that in-
terferes with several life domains and has no clear triggers,
such as bowel movements, food, or menses. It may be at the
far end of the spectrum of other FGIDs, such as IBS. Our
newest disorder, NBS/opioid-induced GI hyperalgesia is
characterized by the paradoxical development of worsening
abdominal pain associated with increased use of opioids.
The only treatment for NBS is to withdraw opioids, which
requires a thoughtful and collaborative approach. Both CAPS
and NBS require a substantial research effort over the next
several years to more fully charaterize their prevalence and
features, understand their unique pathophysiology and
identify more effective therapeutic targets.References
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